Literature DB >> 15599665

In vitro and in vivo antioxidant activity of ambroxol.

V Stetinová1, V Herout, J Kvetina.   

Abstract

In addition to a mucolytic action, ambroxol has antioxidant and anti-inflammatory properties. The antioxidant effects of ambroxol were studied both in vitro and in vivo. In vitro methods, such as (1) inhibition of hyaluronic acid degradation induced by hydroxy radicals and (2) standard lipid peroxidation assay in rat liver mitochondria and gastric mucosa, induced by tert-butyl hydroperoxide, were used. The in vivo approach was based on the study of the protective effect of pretreatment with ambroxol in a rat model of gastric corpus and antral lesions, induced by indomethacin. The inhibition of the degradation of hyaluronic acid was measured as a change of its viscosity; ambroxol (1,000 microl/l) reduced the degradation by 93%. Lipid peroxidation with tert-butyl hydroperoxide as a source of radicals was followed by the formation of thiobarbituric acid reactive substances. Ambroxol (10 mmol/l) inhibited lipid peroxidation by 96% in the rat liver mitochondria, and by 74% in the gastric mucosa. In vivo, ambroxol was administered p.o. at a dose of 10, 30, and 50 mg/kg, at 5, 30, and 60 min prior to indomethacin administration. The highest inhibition of the number of corpus gastric lesions and lowering of the lesion index (38% and 62%, respectively) was shown after the administration of 50 mg/kg, 30 min before indomethacin administration. Antral lesions were inhibited to a lesser extent by the same dose of ambroxol, administered 30 min before indomethacin treatment. Inhibition of the number of antral lesions reached 27% and the total area of the gastric damage was even larger (the ulcer index reached -5%).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15599665     DOI: 10.1007/s10238-004-0050-3

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  7 in total

1.  Pharmacokinetics of ambroxol and clenbuterol tablets in healthy Chinese volunteers.

Authors:  Yong-Ge Yang; Li-Xue Song; Nan Jiang; Xue-Ting Xu; Xiao-Hui Di; Mei Zhang
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 2.  Ambroxol: a CNS drug?

Authors:  Thomas Weiser
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

Review 3.  Therapeutic approaches to mucus hypersecretion.

Authors:  Atsushi Yuta; James N Baraniuk
Journal:  Curr Allergy Asthma Rep       Date:  2005-05       Impact factor: 4.919

4.  Does Ambroxol alleviate kidney ischemia-reperfusion injury in rats?

Authors:  Çağrı Gültekin; Serkan Sayiner; Şule Çetinel; Ahmet Özer Şehirli
Journal:  Iran J Basic Med Sci       Date:  2022-08       Impact factor: 2.532

5.  Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.

Authors:  Alisdair McNeill; Joana Magalhaes; Chengguo Shen; Kai-Yin Chau; Derralyn Hughes; Atul Mehta; Tom Foltynie; J Mark Cooper; Andrey Y Abramov; Matthew Gegg; Anthony H V Schapira
Journal:  Brain       Date:  2014-02-25       Impact factor: 13.501

6.  Ambroxol for the treatment of fibromyalgia: science or fiction?

Authors:  Kai-Uwe Kern; Myriam Schwickert
Journal:  J Pain Res       Date:  2017-08-16       Impact factor: 3.133

Review 7.  The past, present and future of RNA respiratory viruses: influenza and coronaviruses.

Authors:  Vadim Makarov; Olga Riabova; Sean Ekins; Nikolay Pluzhnikov; Sergei Chepur
Journal:  Pathog Dis       Date:  2020-10-07       Impact factor: 3.166

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.